U.S. pharma huge copyright scrapped two experimental weight loss drugs final year—a once-day-to-day tablet, lotiglipron, resulting from elevated liver enzymes in addition to a twice-day by day capsule, danuglipron, due to solid Uncomfortable side effects—but CEO Albert Bourla has sta